CELG News 147.32 05/19/2014 04:34:21 Celgene Corp (CELG)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celgene Corp (CELG) 147.32 $CELG

3 Companies Frightened by This Medicare Study
Todd Campbell, The Motley Fool - Motley Fool - Sun May 18, 6:05AM CDT
Everyone knows that medical costs are soaring, and that those costs present one of the biggest financial challenges to the next generation. But far fewer know that one of the biggest drug buyers, the Centers for Medicare and Medicaid Services, or...

Final Glance: Biotechnology companies
AP - Fri May 16, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

After Yesterday's Decline of 1.03%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Fri May 16, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Watch for Celgene to Potentially Rebound After Falling 1.03% Yesterday
Comtex SmarTrend(R) - Fri May 16, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.30 to a high of $150.20. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $148.00 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Midday Glance: Biotechnology companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

Early Glance: Biotechnology companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Upcoming Conferences, Stock Price Movements and Support to Humanitarian Programs - Analyst Notes on Celgene, Biogen Idec, Incyte, Jazz Pharmaceuticals and Medivation
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Incyte Corporation (NASDAQ: INCY), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Medivation Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2548-100free.

Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2014
Business Wire - Wed May 14, 4:19PM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced more than 65 abstracts reporting on investigational studies in blood and solid tumor cancers will be presented during the 50th American Society of Clinical Oncology meeting in Chicago, Ill. from May 30 to June 3, 2014.

Critical Alerts For DirecTV, JPMorgan, First Solar, Celgene, and Baidu.com Released By InvestorsObserver
PR Newswire - Wed May 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DTV, JPM, FSLR, CELG, and BIDU.

Clinical Trial Results, Acquisitions, Healthcare Partnership, and Pricing of Senior Notes - Analyst Notes on Merck, JNJ, Chelsea, Unitedhealth and Celgene
PR Newswire - Tue May 13, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Unitedhealth Group, Inc. (NYSE: UNH) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2377-100free.

Celgene Rises 2.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 12, 4:00PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.63% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 12, 3:59PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $145.70 to a high of $151.00. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $147.99 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Will Patterson (PDCO) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 12:00PM CDT
Patterson's (PDCO) bottom-line growth was on par with the Zacks Consensus Estimate.

Celgene Earnings Review: 18 Days after Announcement Shares Up 3.8% (CELG)
Comtex SmarTrend(R) - Mon May 12, 11:09AM CDT
When Celgene (NASDAQ:CELG) reported earnings 18 days ago on April 24th, 2014, analysts, on average, expected the company to report earnings of $1.65 on sales of $1.8 billion. The company actually reported EPS of $1.67 on sales of $1.7 billion, beating EPS estimates by $0.02 and missing revenue estimates by $35.1 million. Shares of Celgene have climbed from $141.25 to $146.67, representing a gain of 3.8% since the company reported earnings 18 days ago.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 342

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 13

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Corporation's Manager Transactions Highlight Executive Moves

Updated Category News Views 133

Understanding Orion Corporation's Executive Transactions Orion Corporation, a prominent player in the global pharmaceutical industry, has recently disclosed significant transactions involving its management, shedding light on financial movements that reflect company growth and strategy. Key Details on Managerial Transactions Recently, Orion Corporation reported under the...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 150

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading
Investigating Claims for StubHub Investors: Your Options

Updated Category News Views 173

Investigation of Claims on Behalf of StubHub Investors Faruqi & Faruqi, LLP, a prominent name in national securities law, is currently looking into potential claims related to StubHub Holdings, Inc. (NYSE: STUB). This initiative aims to assist investors who might have faced losses due to the misleading statements made about the company's financial performance during its...

Continue Reading
Sarepta Therapeutics Faces Class Action Amid Safety Concerns

Updated Category News Views 256

Introduction to Sarepta Therapeutics Sarepta Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those associated with genetic factors. The company is well-known for its gene therapy treatments and aims to revolutionize treatment options for patients with Duchenne muscular dystrophy and similar...

Continue Reading